Kidney cancer, version 2.2014.
暂无分享,去创建一个
S. Hancock | R. Motzer | E. Jonasch | T. Choueiri | N. Agarwal | S. Bhayani | Sam S. Chang | I. Derweesh | E. Lam | C. Lau | M. Michaelson | T. Olencki | E. Plimack | B. Redman | B. Somer | M. Dwyer | Rashmi Kumar | T. Kuzel | J. Sheinfeld | D. Lin | C. Beard | R. Pili | C. Ryan | K. Sircar | K. Margolin | G. Bolger | R. Wilder | Shilpa Gupta | Jenny J. Kim | E. Rampersaud | E. Levine | Jue Wang
[1] J. Manola,et al. ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Robert J. Jones,et al. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma , 2013, BMC Urology.
[3] Lisa L. Smith,et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. , 2012, European urology.
[4] R. Shah,et al. Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma: Clinicopathologic Analysis of 52 Cases of Rare Aggressive Subtypes of Renal Cell Carcinoma With a Focus on Their Interrelationship , 2012, The American journal of surgical pathology.
[5] J. Ahn,et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Manola,et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 , 2012, Medical Oncology.
[7] V. Reuter,et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma , 2012, Investigational New Drugs.
[8] J. Dutcher,et al. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy , 2011, Medical oncology.
[9] C. Bokemeyer,et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] T. Choueiri,et al. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. , 2011, Hematology/oncology clinics of North America.
[11] T. Olencki,et al. Bevacizumab in metastatic papillary renal cell carcinoma (PRCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] T. Christmas,et al. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] E. Jonasch,et al. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Choueiri,et al. Pazopanib: Clinical development of a potent anti-angiogenic drug. , 2011, Critical reviews in oncology/hematology.
[15] J. Hajdenberg,et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America , 2010, Cancer.
[16] W. Samlowski,et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Porta,et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.
[18] B. Delahunt,et al. Uncommon and recently described renal carcinomas , 2009, Modern Pathology.
[19] R. Figlin,et al. Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies , 2009, Medical oncology.
[20] Jeffrey P. MacKeigan,et al. Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.
[21] P. Thall,et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. , 2008, The Journal of urology.
[22] G. Sonpavde,et al. Axitinib for renal cell carcinoma , 2008, Expert opinion on investigational drugs.
[23] R. Ghavamian,et al. Renal medullary carcinoma: the Bronx experience. , 2007, Urology.
[24] A. Billis,et al. Renal medullary carcinoma: report of seven cases from Brazil , 2007, Modern Pathology.
[25] M. Guba,et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis , 2007, Cancer and Metastasis Reviews.
[26] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[27] S. Culine,et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.
[28] N. Rioux-Leclercq,et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. , 2007, European urology.
[29] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[30] S. Naito,et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. , 2006, The Journal of urology.
[31] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[32] N. Rioux-Leclercq,et al. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience , 2005 .
[33] M. Milowsky,et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.
[34] E. Small,et al. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Cheville,et al. Sarcomatoid Renal Cell Carcinoma: An Examination of Underlying Histologic Subtype and an Analysis of Associations With Patient Outcome , 2004, The American journal of surgical pathology.
[36] J. Cheville,et al. Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma , 2003, The American journal of surgical pathology.
[37] V. Sukhatme,et al. Renal cancer: molecular mechanisms and newer therapeutic options , 2002, Current opinion in nephrology and hypertension.
[38] G. Sledge,et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[40] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[41] W. Linehan,et al. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. , 2012, The oncologist.
[42] A. Ravaud,et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Picken,et al. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. , 2007, American journal of clinical pathology.
[44] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.